BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 38587361)

  • 21. Staging, response to therapy, and restaging of lymphomas with 18F-FDG PET.
    Altamirano J; Esparza JR; de la Garza Salazar J; Calvo PS; Vera SR; Chalapud Revelo JR; Estrada G
    Arch Med Res; 2008 Jan; 39(1):69-77. PubMed ID: 18067998
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Utility of
    Jitani AK; Dutta S; Mandal PK; De R; Jajodia E; Baul S; Chakrabarti P; Dolai TK
    Indian J Med Res; 2021 May; 154(5):691-698. PubMed ID: 35532587
    [TBL] [Abstract][Full Text] [Related]  

  • 23. FDG PET in the management of lymphoma: a clinical perspective.
    Hoskin PJ
    Eur J Nucl Med Mol Imaging; 2002 Apr; 29(4):449-51. PubMed ID: 11914880
    [No Abstract]   [Full Text] [Related]  

  • 24. Roles and limitations of FDG PET in pediatric non-Hodgkin lymphoma.
    Nakatani K; Nakamoto Y; Watanabe K; Saga T; Higashi T; Togashi K
    Clin Nucl Med; 2012 Jul; 37(7):656-62. PubMed ID: 22691506
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Positron emission tomography with [(18)F]FDG for therapy response monitoring in lymphoma patients.
    Spaepen K; Stroobants S; Verhoef G; Mortelmans L
    Eur J Nucl Med Mol Imaging; 2003 Jun; 30 Suppl 1():S97-105. PubMed ID: 12709831
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of whole-body (18)F-FDG PET imaging on clinical staging and management of patients with malignant lymphoma.
    Schöder H; Meta J; Yap C; Ariannejad M; Rao J; Phelps ME; Valk PE; Sayre J; Czernin J
    J Nucl Med; 2001 Aug; 42(8):1139-43. PubMed ID: 11483671
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Positron emission tomography with [18F]2-fluoro-D-2-deoxyglucose (FDG-PET) predicts relapse of malignant lymphoma after high-dose therapy with stem cell transplantation.
    Becherer A; Mitterbauer M; Jaeger U; Kalhs P; Greinix HT; Karanikas G; Pötzi C; Raderer M; Dudczak R; Kletter K
    Leukemia; 2002 Feb; 16(2):260-7. PubMed ID: 11840293
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The role of PET imaging in lymphoma.
    Burton C; Ell P; Linch D
    Br J Haematol; 2004 Sep; 126(6):772-84. PubMed ID: 15352980
    [TBL] [Abstract][Full Text] [Related]  

  • 29. New staging and response criteria for non-Hodgkin lymphoma and Hodgkin lymphoma.
    Cheson BD
    Radiol Clin North Am; 2008 Mar; 46(2):213-23, vii. PubMed ID: 18619377
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evaluation of Diffusion-Weighted Magnetic Resonance Imaging for Follow-up and Treatment Response Assessment of Lymphoma: Results of an 18F-FDG-PET/CT-Controlled Prospective Study in 64 Patients.
    Mayerhoefer ME; Karanikas G; Kletter K; Prosch H; Kiesewetter B; Skrabs C; Porpaczy E; Weber M; Knogler T; Sillaber C; Jaeger U; Simonitsch-Klupp I; Ubl P; Müllauer L; Dolak W; Lukas J; Raderer M
    Clin Cancer Res; 2015 Jun; 21(11):2506-13. PubMed ID: 25733598
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Positron emission tomography/computed tomography: diagnostic accuracy in lymphoma.
    Hernandez-Maraver D; Hernandez-Navarro F; Gomez-Leon N; Coya J; Rodriguez-Vigil B; Madero R; Pinilla I; Martin-Curto LM
    Br J Haematol; 2006 Nov; 135(3):293-302. PubMed ID: 17032175
    [TBL] [Abstract][Full Text] [Related]  

  • 32. 18F-FDG PET in malignant lymphoma: significance of positive findings.
    Castellucci P; Zinzani P; Pourdehnad M; Alinari L; Nanni C; Farsad M; Battista G; Tani M; Stefoni V; Canini R; Monetti N; Rubello D; Alavi A; Franchi R; Fanti S
    Eur J Nucl Med Mol Imaging; 2005 Jul; 32(7):749-56. PubMed ID: 15785956
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Diagnostic performance of prospective same-day 18F-FDG PET/MRI and 18F-FDG PET/CT in the staging and response assessment of lymphoma.
    Mistry V; Scott JR; Wang TY; Mollee P; Miles KA; Law WP; Hapgood G
    Cancer Imaging; 2023 Jan; 23(1):11. PubMed ID: 36694244
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Positron emission tomography using F-18 fluorodeoxyglucose pre- and post-autologous stem cell transplant in non-Hodgkin's lymphoma.
    Johnston PB; Wiseman GA; Micallef IN
    Bone Marrow Transplant; 2008 Jun; 41(11):919-25. PubMed ID: 18391991
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pediatric Extranodal Lymphoma.
    Chung EM; Pavio M
    Radiol Clin North Am; 2016 Jul; 54(4):727-46. PubMed ID: 27265605
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Fluorine-18 fluorodeoxyglucose PET-CT for extranodal staging of non-Hodgkin and Hodgkin lymphoma.
    Ömür Ö; Baran Y; Oral A; Ceylan Y
    Diagn Interv Radiol; 2014; 20(2):185-92. PubMed ID: 24412817
    [TBL] [Abstract][Full Text] [Related]  

  • 37. FDG-PET in the detection of bone marrow disease in Hodgkin's disease and aggressive non-Hodgkin's lymphoma and its impact on clinical management.
    Pelosi E; Penna D; Deandreis D; Chiappella A; Skanjeti A; Vitolo U; Bisi G
    Q J Nucl Med Mol Imaging; 2008 Mar; 52(1):9-16. PubMed ID: 18235420
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Imaging for diagnosis, staging and response assessment of Hodgkin lymphoma and non-Hodgkin lymphoma.
    McCarten KM; Nadel HR; Shulkin BL; Cho SY
    Pediatr Radiol; 2019 Oct; 49(11):1545-1564. PubMed ID: 31620854
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pediatric nonlymphoblastic non-Hodgkin lymphoma: baseline, interim, and posttreatment PET/CT versus contrast-enhanced CT for evaluation--a prospective study.
    Bakhshi S; Radhakrishnan V; Sharma P; Kumar R; Thulkar S; Vishnubhatla S; Dhawan D; Malhotra A
    Radiology; 2012 Mar; 262(3):956-68. PubMed ID: 22357895
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of fluorine-18 fluorodeoxyglucose positron emission tomography and Ga-67 scintigraphy in evaluation of lymphoma.
    Kostakoglu L; Leonard JP; Kuji I; Coleman M; Vallabhajosula S; Goldsmith SJ
    Cancer; 2002 Feb; 94(4):879-88. PubMed ID: 11920454
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.